Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paracetamol + ropivacaine is a combination of two drugs used for perioperative and postoperative pain management, particularly in surgical settings such as pediatric hypospadias repair. Paracetamol (also known as acetaminophen) is an analgesic and antipyretic that acts centrally to inhibit prostaglandin synthesis, thereby reducing pain and fever. Ropivacaine is an amide-type local anesthetic that blocks nerve impulse conduction by inhibiting sodium channels in neuronal membranes, resulting in loss of sensation or pain relief at the site of administration. This combination may be administered with paracetamol given intravenously and ropivacaine delivered via caudal or regional anesthesia routes. The rationale for combining these agents is to enhance postoperative analgesia; however, clinical studies have shown mixed results regarding additional benefit over ropivacaine alone[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + ropivacaine.